Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Jan 26, 2021

SELL
$12.16 - $19.77 $129,844 - $211,104
-10,678 Closed
0 $0
Q3 2020

Oct 23, 2020

SELL
$11.25 - $14.75 $3.31 Million - $4.34 Million
-294,505 Reduced 96.5%
10,678 $139,000
Q2 2020

Aug 14, 2020

SELL
$10.69 - $16.49 $125,554 - $193,675
-11,745 Reduced 3.71%
305,183 $3.46 Million
Q1 2020

May 13, 2020

SELL
$9.78 - $29.53 $632,501 - $1.91 Million
-64,673 Reduced 16.95%
316,928 $4.54 Million
Q4 2019

Feb 03, 2020

SELL
$20.93 - $35.1 $648,411 - $1.09 Million
-30,980 Reduced 7.51%
381,601 $10.4 Million
Q3 2019

Nov 08, 2019

SELL
$22.08 - $47.08 $621,706 - $1.33 Million
-28,157 Reduced 6.39%
412,581 $11.8 Million
Q2 2019

Aug 05, 2019

SELL
$22.67 - $35.0 $886,374 - $1.37 Million
-39,099 Reduced 8.15%
440,738 $12.2 Million
Q1 2019

May 10, 2019

BUY
$26.93 - $34.7 $193,896 - $249,840
7,200 Added 1.52%
479,837 $15.9 Million
Q4 2018

Feb 05, 2019

SELL
$27.23 - $45.56 $672,417 - $1.13 Million
-24,694 Reduced 4.97%
472,637 $13.7 Million
Q3 2018

Nov 13, 2018

SELL
$37.57 - $50.34 $2.98 Million - $4 Million
-79,442 Reduced 13.77%
497,331 $22.9 Million
Q2 2018

Aug 08, 2018

SELL
$27.75 - $40.17 $2.84 Million - $4.11 Million
-102,270 Reduced 15.06%
576,773 $21.6 Million
Q1 2018

May 11, 2018

SELL
$28.83 - $41.01 $935,360 - $1.33 Million
-32,444 Reduced 4.56%
679,043 $20.1 Million
Q4 2017

Feb 12, 2018

SELL
$28.45 - $37.14 $1.93 Million - $2.52 Million
-67,794 Reduced 8.7%
711,487 $24.4 Million
Q3 2017

Nov 13, 2017

SELL
$24.01 - $36.2 $519,816 - $783,730
-21,650 Reduced 2.7%
779,281 $28.2 Million
Q2 2017

Aug 09, 2017

BUY
N/A
800,931
800,931 $20.7 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.03B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Pinnacle Associates LTD Portfolio

Follow Pinnacle Associates LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinnacle Associates LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pinnacle Associates LTD with notifications on news.